Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-flexible-dose Study of Lu AF11167 for the Treatment of Persistent Prominent Negative Symptoms in Patients With Schizophrenia

Next Previous
Search
Trial Profile

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-flexible-dose Study of Lu AF11167 for the Treatment of Persistent Prominent Negative Symptoms in Patients With Schizophrenia

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lu AF11167 (Primary)
  • Indications Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Lundbeck A/S

    • Most Recent Events

    • 12 Jun 2022 Results (n=162) of this study and the open-label extension study reporting data collected up to study termination, were published in the European Neuropsychopharmacology.
    • 08 Nov 2020 This trial is Completed in Poland (Global End Date: 03 Sep 2020), according to European Clinical Trials Database record.
    • 17 Oct 2020 This trial has been completed in Hungary.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top